The European Commission approved Sanofi Pasteur’s 6-in-1 pediatric vaccine HexyonTM/Hexacima® (DTaP-IPV-Hib-HepB vaccine) for primary and booster vaccination of infants from six weeks of age.
HexyonTM/Hexacima® is the only fully liquid, ready to use 6-in-1 vaccine to protect infants against diphtheria, tetanus, pertussis (whooping cough), Hepatitis B, poliomyelitis and invasive infections caused by Haemophilus influenzae type b.
The new vaccine will be commercialized under the brand name Hexacima® in Eastern European countries by Sanofi Pasteur and under the brand name HexyonTM in Western European countries by Sanofi Pasteur MSD, the joint venture between MSD and Sanofi Pasteur.
The new 6-in-1 vaccine will be available in international markets under the trade name Hexaxim®.
DENGUE CHARTS & GRAPHICS